Authors:
Passi, P
Zadro, A
Marsilio, F
Lora, S
Caliceti, P
Veronese, FM
Citation: P. Passi et al., Plain and drug loaded polyphosphazene membranes and microspheres in the treatment of rabbit bone defects, J MAT S-M M, 11(10), 2000, pp. 643-654
Authors:
Boni, C
Bisagni, G
Savoldi, L
Moretti, G
Rondini, E
Sassi, M
Zadro, A
De Pas, T
Franciosi, V
Pazzola, A
Vignoli, R
Banzi, MC
Pajetta, V
Citation: C. Boni et al., Gemcitabine, ifosfamide, cisplatin (GIP) for the treatment of advanced non-small cell lung cancer: A phase II study of the Italian oncology group forclinical research (GOIRC), INT J CANC, 87(5), 2000, pp. 724-727
Authors:
Cocconi, G
Bisagni, G
Ceci, G
Blasio, BD
De Lisi, V
Passalacqua, R
Zadro, A
Boni, C
Morandi, P
Savoldi, L
Citation: G. Cocconi et al., Three new active cisplatin-containing combinations in the neoadjuvant treatment of locally advanced and locally recurrent breast carcinoma: a randomized phase II trial, BREAST CANC, 56(2), 1999, pp. 125-132
Authors:
Boni, C
Savoldi, L
Bisagni, G
Ceci, G
Crino, L
De Lisi, V
Di Costanzo, F
Lasagni, L
Manenti, AL
Moretti, G
Rondini, E
Sassi, M
Zadro, A
Citation: C. Boni et al., Bolus versus 5-day continuous infusion of cisplatin with mitomycin and vindesine in the treatment of advanced non-small cell lung cancer (NSCLC): A phase III prospective randomised trial of the Italian Oncology Group for Clinical Research (GOIRC), EUR J CANC, 34(12), 1998, pp. 1974-1976
Authors:
Bisagni, G
Boni, C
Manenti, AL
Moretti, G
Rondini, E
Sassi, M
Zadro, A
Savoldi, L
Citation: G. Bisagni et al., Ifosfamide bolus followed by five days continuous infusion in extensively pretreated patients with advanced breast cancer: A phase II study, TUMORI, 84(6), 1998, pp. 659-661